



AFRICAN JOURNAL OF CLINICAL AND EXPERIMENTAL MICROBIOLOGY       MAY 2012             ISBN 1595-689X    VOL 13(2) 
AJCEM/201179/21203                              -http://www.ajol.info/journals/ajcem 
COPYRIGHT 2012 
AFR. J. CLN. EXPER. MICROBIOL 13(2):61-65 http://dx.doi.org/10.4314/ajcem.v13i2.1 
 
MOLECULAR EPIDEMIOLOGY OF HEPATITIS C VIRUS (HCV) IN KADUN STATE. 
 
Sheyin, Z1*., Jatau, E D2., Mamman, A. I3., Randawa, A J4. 
 
1. Hajiya Gambo Sawaba General Hospital Zaria, Kaduna State Ministry of Health. 2. Department of Microbiology, Ahmadu 
Bello University, Zaria, 3. Department of Haematology Ahmadu Bello University Teaching Hospital, Zaria, 4. Department of 
Obstetric & Gynaecology, Ahmadu Bello University Teaching Hospital, Zaria. 
 
*Correspondence:  Phone number 08023792784 E-mail sheyinzakka@yahoo.com 
 
ABSTRACT. 
Objective: To determine the distribution of hepatitis C virus (HCV) genotypes and subtypes among blood donors and outpatients 
attendees positive for antibody to HCV (anti-HCV).   
Justification: Hepatitis C virus (HCV) continues to be a major disease burden on the world and Man is the only known natural 
host of Hepatitis C virus (Chivaliez and Pawlotsky, 2007).    . There is no published data on the prevalence of the genotypes and 
subtypes of HCV in Kaduna State. 
Setting: Three hospitals one in each of the 3 senatorial zones in Kaduna State.   
Patients: Blood donors who reported for blood donation and outpatient department attendees.  
Method: Antibody detection by a third generation HCV ELISA (Biotech Laboratories, UK); HCV RNA and genotyping by Reverse 
Transcriptase polymerase chain reaction with genotype-specific primers. (Sacace Biotechnologies, UK). 
Results: of the 259 plasma specimens screened for Hepatitis C virus in this study, 20(7.7%) were positive for anti-HCV antibodies 
by ELISA and 16(6.2%) of the antibodies positive specimen were positive for HCV RNA. Of the 139 blood donors tested, 8 (5.8%) 
were HCV RNA positive. Similarly, 120 were tested from the outpatient Department attendees and 8 (6.7%) were HCV RNA 
positive. Hepatitis C virus genotype 1b was found in the entire HCV RNA positive sample.  
Conclusions: The findings of 6.2% prevalence of   HCV infection based on HCV RNA test confirmed that there is Hepatitis C 
virus in Kaduna State with genotype 1b as the predominant genotype found in all the three senatorial zones. 
INTRODUCTION 
Blood test were developed to identify hepatitis B in 
1963 and hepatitis A in 1973, but many of the blood 
samples taken for post transfusion illness tested 
negative for hepatitis A and Hepatitis B. The 
unidentified cases were classified as non A, non B 
hepatitis (1, 2). In the 1980’s, investigators from the 
centre for disease and control and Chiron Corporation 
identified the virus to be Hepatitis C virus (2). In 1990, 
blood banks began screening blood donors for 
hepatitis C, and it was not until 1992 that a blood test 
was perfected that effectively eliminated HCV from 
the blood transfusion supply (2, 3). It is now believed 
that approximately 90 to 95% of cases previously 
classified as non A, non B hepatitis were actually 
hepatitis C (3). Hepatitis C virus (HCV) is a member of 
the family Flaviviridae, placed in a new monotypic 
genus-Hepacivirus (4, 5). The viral genome is a single-
stranded RNA molecule approximately 9.6 kb in 
length which is positive sense and possesses a unique 
open reading frame, coding for a single polyprotein, 
flanked by untranslated regions at both its 5′ and 3′  
 
ends. The length of the polyprotein-encoding region 
varies according to the isolate and genotype of the 
virus from 3008 to 3037 amino acids (6). The genus 
Hepacivirus consists of 6 major genotypes further  
 
divided into subtypes (7). HCV genotypes 1, 2 and 3 
are the most commonly detected types worldwide (8). 
Genotype 1 in particular has been extensively reported 
by other authors in Brazil (9), Chile (10), Uruguay (11), 
Argentina (12) and Venezuela (13). HCV genotype 1a, 
1b originated about 100 years ago and are evolving at 
faster rate than genotypes 4 and 6 (8). 
 
 The genotypes can be distinguished by whole genome 
or genome fragment sequencing, genotype specific 
amplification of a genomic region or PCR 
amplification followed by hybridization or restriction 
digestion among other methods (3, 14). In the United 
States of America, the incidence of post transfusion 
HCV dropped from 3.84% to 0.57% after HCV 
screening was introduced in 1990. The incidence of 
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transfusion-related HCV is however still higher in 
developing countries (15). Nigeria belongs to the 
group of countries highly endemic for viral hepatitis 
including HCV. The prevalence of HCV among blood 
donors ranges from 6.0% to 9.5% (16, 17, 18). However, 
there is no knowledge of HCV RNA prevalence in 
Kaduna state. 
 
MATERIALS AND METHODS.  
Ethical approval was obtained from the ethical 
committee of the Ahmadu Bello University Teaching 
Hospital Shika-Zaria and from the Directors of General 
Hospital Kafanchan and Yusuf Dantsoho Hospital 
Tudun Wada Kaduna. Informed consent form written 
in English and Hausa was administered to each person 
whose blood was collected. Two hundred and fifty 
nine (259) blood samples were collected from 139 
blood donors and 120 outpatient department attendees 
in three hospitals one in each of the three senatorial 
zones in Kaduna state using systematic sampling 
method. Blood samples (5ml) were collected into blood 
bottles containing anticoagulant. The plasma samples 
were separated into sterile bottles by centrifugation at 
1000 rpm for 30 minutes and the plasma samples were 
stored at -20οC initially in the various hospitals and 
were later transported by cold box and stored at -20οC 
in Virology laboratory at the Department of 
Microbiology, Ahmadu Bello University Zaria 
immediately until required for the analysis. 
 
HCV ANTIBODY DETECTION BY HCV ELISA 
(BIOTEC U.K) 
The plasma samples were initially tested for the 
presence of Hepatitis C virus antibodies using a 
commercially available third generation HCV Enzyme-
linked immunosorbent assay (Biotech Laboratories, 
1P53RG.UK.). The procedure according to the 
manufacturer was used. The plates were read 
according to manufacturer’s instruction as follows: 
The wells were assessed visually immediately after the 
second incubation. Medium to dark blue colour 
indicated positive result. 
No colour or very pale colour indicated negative 
result. The intensity of the reaction was 
photometrically quantitated with a dual filter Enzyme 
Immuno Assay Reader (Sigma diagnostics EIA Multi-
well Reader 11) immediately using O.D at 450nm, 
630nm.  
 
REVERSE TRANSCRIPTION POLYMERASE 
CHAIN REACTION (RT-PCR). 
HCV RNA Extraction procedure. 
 The lysis solution and washing solution were brought 
to 65οC and Lysis solution (450µl) and 100µl of 
samples were added to appropriate labelled tubes.  All 
tubes were vortexed and centrifuged for 30 sec. 
Sorbent was vortexed vigorously and 25µl were added 
to each tube and all tubes were vortexed for 7 sec and 
were incubated at room temperature for 10 minutes. 
The tubes were vortexed periodically during 
incubation. The tubes were centrifuged for 30 sec at 
10,000(rpm) and the supernatants were discarded 
without disturbing the pellet using fresh pipette tips. 
Washing solution (400µl) was added to each tube 
vortexed vigorously and were centrifuged for 30 sec at 
10,000rpm. The supernatants were then carefully 
removed without disturbing the pellet using fresh 
pipette tips. Seventy percent ethanol (500µl) was 
added to each tube and was vortexed vigorously and 
was centrifuged for 30 sec at 10,000rpm. The 
supernatant was carefully removed and discarded 
from each tube without disturbing the pellet using 
fresh pipette tips. The procedure in this step was 
repeated. Acetone (400µl) was added to each tube and 
was vortexed vigorously and was centrifuged for 30 
sec at 10,000rpm. The supernatants were carefully 
removed without disturbing the pellet with fresh tips 
between tubes. All tubes were incubated with open 
cap for 10minutes at 60οC. The pellets were re-
suspended in 50µl of RNA-diluents and were 
incubated for 10 minutes at 60οC and were vortexed 
periodically during incubation. The tubes were 
centrifuged for 1 minute at maximum speed of 
16,000rpm. The supernatant which contain the RNA 





Preparation of Reaction Mix for 12 Reactions  
RT-G-mix-1 (5µl) was added into tube containing RT-
Mix, vortexed for 10 sec and was briefly  
centrifuged. M-MLV (6µl) was added into tube with 
reaction mixed,  vortexed and centrifuged  
for 7sec. This was immediately used for reverse 
transcription. 
Reverse Transcription 
Reaction mix (10µl) was added to each tube. The tubes 
with extracted RNA were re-centrifuged for 2 minutes 
at 16,000rpm. Supernatants containing extracted RNA 
(10µl) were taken to appropriate tubes. The tubes were 
placed into thermocycler(Techgene, model FTGENE 
5D, Serial NO 121254-4) and were incubated at 37οC 
for 30 minutes. Each cDNA sample obtained was 
diluted 1:2 with T E-buffer [20µl of T E buffer was 
added to each tube] and was ready for used.      
 
Enzymes and oligonucleotide primers for the 
polymerase chain reaction. 
Taq deoxyribonucleic acid (DNA) polymerase and 
moloney murine leukemia virus (M-MLV) reverse 
transcriptase were obtained from (Sacace 
Biotechonologies, Italy). Primers utilized were specific 
for region of HCV genome with the 338bp for 
genotype 1a, 395bp for genotype 1b, 286bp for 
genotype 2, and 227bp for genotype 3a. Primers 







5’-TATGTTCAACAGCAAGGGCCAGA-3’ (for 2).  
5’-CTCGGACCCTGACTTTCT-3’ (for 3a)  
5’-CCTGGTCATAGCCTCCGTGAA-3’ (antisense 
primer for all genotypes). 
 
Polymerase Chain Reaction using HCV genotype 
specific primers.  
Tubes (12) of PCR Mix-1 genotypes 1a/1b tubes and 12 
of PCR Mix-1 genotypes 2/3a including 1 tube for 
negative control and 1tube for positive control were 
prepared. PCR Mix-2 (10µl) was added to each tube. 
cDNA samples obtained after RT step (5µl) were 
added to appropriate tubes. DNA buffer (5µl) was 
added to negative control tube of amplification. cDNA 
1a (5µl ) was added to the PCR-Mix -1 genotype 1a/1b 
tube. cDNA 1b (5µl )were added to the PCR-Mix -1 
genotype 1a/1b tube. cDNA 2 (5µl) were added to the 
PCR Mix-1 genotypes 2/3a tube. cDNA 3a (5µl) were 
added to the PCR Mix-1 genotypes 2/3a tube.  
The tubes were closed and transferred to the 
thermocycler only when temperature reached 95οC. 
The  reactions were started  after the thermocycler was 
programmed. Step 1 (Initial denaturation): 95°C, 5 
minute. Step 2 (42 cycles): Denaturation at 95°C, 1 
minute; annealing at 68°C, 1 minute; extension at 72°C, 
1 minute. Step 3 final extension at 72°C, 1 minute and 





Detection of the PCR Products  
The amplified cDNAs were detected by 
electrophoresis.  
Agarose concentration of 1.0% was melted by boiling 
in microwave oven for 2 minutes. The solubilized 
agarose was cooled down to 65°C and 5µl ethidium 
bromide was added. Formoldehyde (6.5ml) was added 
to every 100ml of gel.  The gel was poured into taped 
gel trays and well-formed combs were placed near the 
edge and middle of gel and were covered with plastic 
box to prevent evaporation and allowed to harden for 
1 hour. Electrophoresis tanks were filled with 10mM 
sodium phosphate buffer. Gel was totally submerged 
in buffer at a level not more than 1cm above the gel 
and the combs were removed. Samples were prepared 
by adding 5µl of gel loading buffer to each 15µl 
sample. Samples were loaded and 75volts was applied 
for 45 minutes.  
The power supply was switch off when dye front has 
run approximately 80% of gel length and the gel trays 
containing the gel were removed. The gel were then 
soaked in 5mM NaoH and blotted into nylon 
membrane. Gels were examined on UV transluminator 
using protective glass. Photographs were taken and 
the resulting photographs were used to determine the 
distance migrated for each band.  
 
Identification of Bands of PCR Products  
The control cDNA for genotypes 1a, 1b, 2, 3a and 
kilobase ladder (used as marker) were used for the 
identification of the bands as shown in figure 1 below. 
The length of specific amplified DNA fragments is:  
HCV genotype 1a – 338 bp, HCV genotype 1b – 395 bp,  
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395bps 
Fig. 1: Shows Agarose gel electrophoresis of HCV RNA using specific primers for genotype 1a, 1b, 2 and 3a. Analysis of the result 
is based on the presence or absence of specific bands of amplified DNA on agarose gel.  Lane M, marker (1000bps);  Lane 1, 3, 5, 7, 
9, 11, 13, 15, 17 & 19, genotypes 1a/1b;  Lane 2, 4, 6, 8, 10, 12, 14, 16, 18 & 20, genotypes 2/3a; Lane C1, positive control for 








DATA ANALYSIS  
The data were analyzed at Data Processing Unit, 
Institute of Agriculture Research (IAR), ABU, Zaria 
using SPSS Software Version 13.0. Chi-square test was 
used at 95% confidence interval (P≤ 0.05). 
 
RESULTS 
Out of the 259 plasma specimens screened for 
Hepatitis C virus in this study, 20(7.7%) were positive 
for anti-HCV antibodies by ELISA and 16(6.2%) of the 
antibodies positive specimen were positive for HCV  
 
 
RNA (Table 1).  The prevalence of HCV per age group 
has shown that 21-40 age group has the highest 
prevalence rate of 14(7.2%) HCV RNA followed by 41-
60 age group with 2(5.6%) HCV RNA, Also, the P 
value (P = 0.735) indicated that there is no significance 
association between age and HCV infection. Of the 139 
blood donors tested, 8 (5.8%) were HCV RNA positive. 
Similarly, 120 were tested from the outpatient 
Department Attendees and 8 (6.7%) were HCV RNA 
positive (Table 2).  
 
Table 1: Distribution of HCV among blood donors and Outpatient Department attendees   in the Senatorial Zones 
 
Zone Number Tested Number (%) Positive 
HCV Ab HCV RNA 
Southern 46 4 (8.6) 4(8.6) 
`Central 130 12 (9.2) 8(6.2) 
Northern 83 4 (4.8) 4(4.8) 
Total 259 20 (7.7) 16(6.2) 
Chi square value = 0.286; P = 0.087 at 95% confidence interval (P≤0.05) 
 
 
Table 2: Age Distribution of HCV Positive Cases 
 














≤ 20  4 0 (0) 24 0 (0) 28 0 (0) 
21 – 40 113 7(6.2) 81 7(8.6) 194 14(7.2) 
41 – 60 22 1(4.5) 14 1(7.1) 36 2(5.6) 
61 – 80 0 0(0) 1 0(0) 1 0(0) 
Total  139 8 (5.8) 120 8(6.7) 259 16 (6.2) 
Chi – Square Value = 2.006; P = 0.735 at 95% Confidence Interval P≤0.05 
 
DISCUSSION 
The prevalence rate of 7.7% anti-HCV antibodies 
found in this study indicated a high prevalence of the 
disease in Kaduna State. It is higher than the earlier 
report of 6.0% HCV prevalence from Jos (16), and 
slightly lower than the 8.4% HCV prevalence reported 
from Abuja (17). The RT-PCR finding of 6.2% HCV 
prevalence is slightly higher than the world Health 
Organization report of 5.3% HCV prevalence rate in  
 
Africa (19). The prevalence of 5.8% HCV infection 
among blood donors and 6.7% HCV prevalence among 
outpatient Department attendees has however shown 
that the outpatient Department attendees had the 
highest prevalence among the study group. This 
confirms that outpatient Department attendees are 
patients seeking medical attention while blood donors 




virus genotypes were determined by RT-PCR with 
HCV specific primers for genotype 1a, 1b, 2 and 3a and 
primers for all other genotypes were also used.  
Genetically, the HCV genotype 1b was found to be the 
genotype in circulation in Kaduna State, while in 
Abuja, genotype 1a and 1b had been reported (17). 
Genotype assignment helps in assessing disease 
prognosis and assist in establishing the appropriate 
dosage and duration of treatment (3, 20). Genotype 
assignment also helps in determining the type of 
vaccine to be used. Currently there is no HCV vaccine. 
The report of HCV genotype 1b in Kaduna State offers 
valuable information for its consideration as a vaccine 
candidate when the search for HCV vaccine seriously 
on course becomes a reality. 
 
CONCLUSION 
The findings of 6.2% prevalence of   HCV infection 
based on HCV RNA test confirmed that there  
is Hepatitis C virus in Kaduna State. Genotype 1b was 
found in all the 16 positive HCV RNA samples. This 
suggests that genotype 1b is the predominant 
genotype in Kaduna state. 
 
RECOMMENDATION 
Hepatitis C virus should be taken seriously and should 
be included among the blood borne pathogen that are 
tested before blood transfusion in government and 
private hospitals in Kaduna state. The health system 
should be strength to support all HCV infected 
persons medically and socially, as well as supporting 
vaccine development research. 
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